In the phase II FINEST trial, 27 patients with HR+/HER2- EBC who were insensitive to chemotherapy (<40% tumor regression after 2 cycles of nab-paclitaxel and carboplatin) receive a combination of adebrelimab (a PD-L1 inhibitor) plus dalpiciclib and letrozole, a regimen conversion that did not increase the pCR rate but improved the ORR and reduced Ki-67 levels [86]. Here, ERBB2 is linked to neoplasm.